Conversion Hepatectomy for Huge Hepatocellular Carcinoma With Arterioportal Shunt After Chemoembolization and Lenvatinib Therapy-Reference-Cited by-同舟云学术

Conversion Hepatectomy for Huge Hepatocellular Carcinoma With Arterioportal Shunt After Chemoembolization and Lenvatinib Therapy

Published:2019-09-30 Issue:10 Volume:39 Page:5695-5701
ISSN:0250-7005
Container-title:Anticancer Research
language:en
Short-container-title:Anticancer Res

Author:

SATO NOBUTAKA,BEPPU TORU,KINOSHITA KOICHI,YUKI HIDEAKI,SUYAMA KOICHI,CHIYONAGA SUGURU,MOTOHARA TOSHIHIKO,KOMOHARA YOSHIHIKO,HARA AKIO,AKAHOSHI SHINICHI

Publisher

Anticancer Research USA Inc.

Subject

Cancer Research,Oncology,General Medicine

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subsequent locoregional therapy prolongs survival in progressive hepatocellular carcinoma patients under lenvatinib treatment;Journal of the Formosan Medical Association;2024-07

2. Current Status of Conversion Hepatectomy After Sorafenib and Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma;Anticancer Research;2024-06-26

3. Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective study;Scientific Reports;2024-04-28

4. A patient alive without disease 32 months after conversion surgery following lenvatinib treatment for hepatocellular carcinoma with a tumor thrombus originating in the middle hepatic vein and reaching the right atrium via the suprahepatic vena cava: a case report;Clinical Journal of Gastroenterology;2024-01-26

5. レンバチニブ及び放射線治療後の再肝切除による集学的治療が奏功した門脈腫瘍栓を伴う早期再発肝細胞癌の1例;Kanzo;2023-12-01